Quantum Biopharma Class B Subordinate Voting Shares
QNTM
12 hedge funds and large institutions have $316K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.
1,608% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $60K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
11% less capital invested
Capital invested by funds: $357K → $316K (-$40.8K)
14% less funds holding
Funds holding: 14 → 12 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$83.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$64.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$54.9K |
| 4 |
RPC
Rossmore Private Capital
Glastonbury,
Connecticut
|
+$41.8K |
| 5 |
FIA
FNY Investment Advisers
New York
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$164K |
| 2 |
VF
Virtu Financial
New York
|
-$27K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$12K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$3.19K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$1K |
QNTM Hedge Fund Activity: Q4 2020 in Review
12 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q4 2020, worth a combined $316K — down 11% from $357K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of QNTM and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $83.8K. The largest seller was Wedbush Securities, exiting entirely with an estimated $164K sold.
- 12 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q4 2020, down from 14 in Q3 2020.
- Funds reported $316K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q4 2020, down 11% quarter-over-quarter.
- 4 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q4 2020 and 6 closed out, a net change of -2 holders.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q4 2020 was Renaissance Technologies, an estimated $83.8K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q4 2020 was Wedbush Securities, an estimated $164K sold.
Based on aggregated 13F filings for Q4 2020.